TRAIL Signals, Extracellular Matrix and Vessel Remodelling

Overview

Journal Vasc Biol

Date 2020 Sep 14

PMID 32923976

Citations 4

Authors

Manisha S Patil

Sian P Cartland

Mary M Kavurma

Affiliations

Soon will be listed here.

Abstract

The extracellular matrix (ECM) is an essential part of the vasculature, not only providing structural support to the blood vessel wall, but also in its ability to interact with cells to regulate cell phenotype and function including proliferation, migration, differentiation and death - processes important in vascular remodelling. Increasing evidence implicates TNF-related apoptosis-inducing ligand (TRAIL) signalling in the modulation of vascular cell function and remodelling under normal and pathological conditions such as in atherosclerosis. TRAIL can also stimulate synthesis of multiple ECM components within blood vessels. This review explores the relationship between TRAIL signals, the ECM, and its implications in vessel remodelling in cardiovascular disease.

Citing Articles

A Possible Phenotype-to-Genotype Association of Novel Single-Nucleotide Variants in the Coding Exons of the Gene to Arterial Aneurysmal and Dissection Diseases.

Wolf A, Moore P, Hong C, Sathyamoorthy M Int J Mol Sci. 2025; 25(24.

PMID: 39769491 PMC: 11678303. DOI: 10.3390/ijms252413730.

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies.

Luo C, He S, Shi F, Zhou J, Shang L Biology (Basel). 2024; 13(7).

PMID: 39056714 PMC: 11274015. DOI: 10.3390/biology13070521.

An emerging view on vascular fibrosis molecular mediators and relevant disorders: from bench to bed.

Hua R, Gao H, He C, Xin S, Wang B, Zhang S Front Cardiovasc Med. 2024; 10:1273502.

PMID: 38179503 PMC: 10764515. DOI: 10.3389/fcvm.2023.1273502.

Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding.

Riera-Domingo C, Leite-Gomes E, Charatsidou I, Zhao P, Carra G, Cappellesso F Sci Adv. 2023; 9(12):eadd5028.

PMID: 36947620 PMC: 10032608. DOI: 10.1126/sciadv.add5028.

Behind the Adaptive and Resistance Mechanisms of Cancer Stem Cells to TRAIL.

Quiroz-Reyes A, Delgado-Gonzalez P, Islas J, Gallegos J, Martinez Garza J, Garza-Trevino E Pharmaceutics. 2021; 13(7).

PMID: 34371753 PMC: 8309156. DOI: 10.3390/pharmaceutics13071062.

References

Fukai N, Kenagy R, Chen L, Gao L, Daum G, Clowes A . Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol. 2009; 29(9):1356-62. PMC: 2729810. DOI: 10.1161/ATVBAHA.109.190132. View

Ponticos M, Smith B . Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res. 2014; 28(1):25-39. PMC: 3904172. DOI: 10.7555/JBR.27.20130064. View

Bennett B, Scatena M, Kirk E, Rattazzi M, Varon R, Averill M . Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26(9):2117-24. DOI: 10.1161/01.ATV.0000236428.91125.e6. View

Wang X, Khalil R . Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018; 81:241-330. PMC: 5765875. DOI: 10.1016/bs.apha.2017.08.002. View

Chen P, Easton A . Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem Biophys Res Commun. 2009; 391(1):936-41. DOI: 10.1016/j.bbrc.2009.11.168. View

Bumdelger B, Kokubo H, Kamata R, Fujii M, Yoshimura K, Aoki H . Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms. PLoS One. 2016; 11(1):e0147088. PMC: 4718675. DOI: 10.1371/journal.pone.0147088. View

Arnold N, Pickworth J, West L, Dawson S, Carvalho J, Casbolt H . A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nat Commun. 2019; 10(1):5183. PMC: 6858314. DOI: 10.1038/s41467-019-13139-9. View

Di Bartolo B, Chan J, Bennett M, Cartland S, Bao S, Tuch B . TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe ⁻/⁻ mice. Diabetologia. 2011; 54(12):3157-67. DOI: 10.1007/s00125-011-2308-0. View

Di Bartolo B, Cartland S, Prado-Lourenco L, Griffith T, Gentile C, Ravindran J . Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms. J Am Heart Assoc. 2015; 4(11). PMC: 4845240. DOI: 10.1161/JAHA.115.002527. View

10.

Suna G, Wojakowski W, Lynch M, Barallobre-Barreiro J, Yin X, Mayr U . Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. Circulation. 2017; 137(2):166-183. PMC: 5757669. DOI: 10.1161/CIRCULATIONAHA.116.023381. View

11.

Galeone A, Brunetti G, Oranger A, Greco G, Di Benedetto A, Mori G . Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. Int J Cardiol. 2013; 169(4):296-304. DOI: 10.1016/j.ijcard.2013.09.012. View

12.

Yue B . Biology of the extracellular matrix: an overview. J Glaucoma. 2014; 23(8 Suppl 1):S20-3. PMC: 4185430. DOI: 10.1097/IJG.0000000000000108. View

13.

Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G . Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis. 2010; 211(1):333-6. DOI: 10.1016/j.atherosclerosis.2010.02.024. View

14.

Schoppet M, Sattler A, Schaefer J, Hofbauer L . Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis. 2005; 184(2):446-7. DOI: 10.1016/j.atherosclerosis.2005.10.028. View

15.

Fingas C, Blechacz B, Smoot R, Guicciardi M, Mott J, Bronk S . A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology. 2010; 52(2):550-61. PMC: 2957364. DOI: 10.1002/hep.23729. View

16.

Yurovsky V . Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol. 2003; 28(2):225-31. DOI: 10.1165/rcmb.2002-0140OC. View

17.

Davenport C, Harper E, Rochfort K, Forde H, Smith D, Cummins P . RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. J Vasc Res. 2018; 55(2):111-123. PMC: 6375687. DOI: 10.1159/000486787. View

18.

Baudhuin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M . Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev. 2013; 24(5):401-9. DOI: 10.1016/j.cytogfr.2013.06.001. View

19.

Kavurma M, Schoppet M, Bobryshev Y, Khachigian L, Bennett M . TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem. 2008; 283(12):7754-62. DOI: 10.1074/jbc.M706927200. View

20.

To W, Midwood K . Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 2011; 4:21. PMC: 3182887. DOI: 10.1186/1755-1536-4-21. View